BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7779413)

  • 1. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
    Olive PL
    Acta Oncol; 1995; 34(3):301-5. PubMed ID: 7779413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
    Olive PL
    Br J Cancer; 1995 Mar; 71(3):529-36. PubMed ID: 7880735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the comet assay to identify cells sensitive to tirapazamine in multicell spheroids and tumors in mice.
    Olive PL; Vikse CM; Banath JP
    Cancer Res; 1996 Oct; 56(19):4460-3. PubMed ID: 8813141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069.
    Olive PL
    Br J Cancer; 1995 Mar; 71(3):537-42. PubMed ID: 7880736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
    Keohane A; Godden J; Stratford IJ; Adams GE
    Br J Cancer; 1990 May; 61(5):722-6. PubMed ID: 2110815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
    Siim BG; van Zijl PL; Brown JM
    Br J Cancer; 1996 Apr; 73(8):952-60. PubMed ID: 8611431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
    Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
    Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions.
    Hwang JT; Greenberg MM; Fuchs T; Gates KS
    Biochemistry; 1999 Oct; 38(43):14248-55. PubMed ID: 10571998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of DNA damage in mammalian cells upon bioreduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131.
    Jenner TJ; Sapora O; O'Neill P; Fielden EM
    Biochem Pharmacol; 1988 Oct; 37(20):3837-42. PubMed ID: 3190731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The experimental development of bioreductive drugs and their role in cancer therapy.
    Workman P; Stratford IJ
    Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of oncogenicity for bioreductive drugs.
    Hei TK; Piao CQ; He ZY; Hall EJ
    Int J Radiat Oncol Biol Phys; 1992; 22(4):747-50. PubMed ID: 1544847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioreductive drugs and the selective induction of tumour hypoxia.
    Bremner JC; Stratford IJ; Bowler J; Adams GE
    Br J Cancer; 1990 May; 61(5):717-21. PubMed ID: 2110814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
    Zhang M; Stevens G
    Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
    Siim BG; Menke DR; Dorie MJ; Brown JM
    Cancer Res; 1997 Jul; 57(14):2922-8. PubMed ID: 9230202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of tumor hypoxia and inhibition of DNA repair by nicotinamide after irradiation of SCCVII murine tumors and normal tissues.
    Zheng H; Olive PL
    Cancer Res; 1996 Jun; 56(12):2801-8. PubMed ID: 8665517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in situ tumour response to combinations of cyclophosphamide and tirapazamine.
    Siemann DW
    Br J Cancer Suppl; 1996 Jul; 27():S65-9. PubMed ID: 8763849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the repair and damage of DNA induced by parent and reduced RSU-1069, a 2-nitroimidazole-aziridine.
    O'Neill P; Cunniffe SM
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):963-6. PubMed ID: 2649467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioreductive therapies: an overview of drugs and their mechanisms of action.
    Rauth AM; Melo T; Misra V
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
    Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Takahashi M; Abe M
    Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.